Rivaroxaban

Drug Profile

Rivaroxaban

Alternative Names: BAY-59-7939; JNJ-39039039; Xarelto

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator Bayer; Johnson & Johnson Pharmaceutical Research & Development
  • Developer Bayer; Janssen Research & Development; Johnson & Johnson; McMaster University; Population Health Research Institute
  • Class Amides; Anticoagulants; Antithrombotics; Morpholines; Oxazolidinones; Small molecules; Thiophenes
  • Mechanism of Action Factor IXa inhibitors; Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Acute coronary syndromes; Cardiovascular disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Embolism; Stroke; Venous thromboembolism
  • Registered Acute coronary syndromes; Deep vein thrombosis; Pulmonary embolism
  • Phase III Atrial fibrillation; Cardiovascular disorders; Peripheral arterial disorders; Thromboembolism; Thrombosis
  • Phase II Coronary thrombosis

Most Recent Events

  • 04 Jan 2017 Phase-I/II clinical trials in Thrombosis (In infants, In neonates) in Israel, France (PO) (NCT02564718)
  • 14 Nov 2016 Interim efficacy and adverse events data from the phase IIIb PIONEER AF-PCI trial in Acute coronary syndrome presented at the 88th Annual Scientific Sessions of the American Heart Association (AHA-2016)
  • 01 Nov 2016 Phase-III clinical trials in Thrombosis (In children, Prevention) in Spain (PO) (NCT02846532)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top